15353-j-veluchamy

1 General introduction and Scope of this Thesis | 31 61. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology (2010) 28 (6):955-9. doi: doi:10.1200/ JCO.2009.24.4590. PubMed PMID: 20085940. 62. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, et al. Allogeneic natural killer cells for refractory lymphoma. Cancer immunology, immunotherapy : CII (2010) 59 (11):1739-44. Epub 2010/08/04. doi: 10.1007/s00262-010-0896-z. PubMed PMID: 20680271; PubMed Central PMCID: PMCPMC4082975. 63. Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, MottaMR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood (2011) 118 (12):3273-9. Epub 2011/07/28. doi: 10.1182/ blood-2011-01-329508. PubMed PMID: 21791425. 64. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, et al. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation inmultiplemyeloma. British journal of haematology (2017). Epub 2017/03/16. doi: 10.1111/bjh.14570. PubMed PMID: 28295190. 65. Choi I, Yoon SR, Park SY, Kim H, Jung SJ, Kang YL, et al. Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia. Biol Blood Marrow Transplant (2016) 22 (11):2065-76. Epub 2016/08/18. doi: 10.1016/j.bbmt.2016.08.008. PubMed PMID: 27530969. 66. Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, et al. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant (2016) 22 (7):1290-8. Epub 2016/04/20. doi: 10.1016/j. bbmt.2016.04.009. PubMed PMID: 27090958; PubMed Central PMCID: PMCPMC4905771. 67. Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation. Blood (2015) 125 (5):784-92. doi: 10.1182/blood-2014-07-592881. 68. Killig M, Friedrichs B, Meisig J, Gentilini C, Bluthgen N, Loddenkemper C, et al. Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation. European journal of immunology (2014) 44 (9):2822-34. Epub 2014/06/05. doi: 10.1002/eji.201444586. PubMed PMID: 24895051. 69. Choi I, Yoon SR, Park SY, Kim H, Jung SJ, Jang YJ, et al. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant (2014) 20 (5):696-704. Epub 2014/02/15. doi: 10.1016/j. bbmt.2014.01.031. PubMed PMID: 24525278. 70. Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, et al. Autologous Stem Cell Transplant Recipients Tolerate Haploidentical Related-Donor Natural Killer Cell Enriched Infusions. Transfusion (2013) 53 (2):412-8. doi: 10.1111/j.1537-2995.2012.03764.x. PubMed PMID: PMC3549470. 71. Stern M, Passweg JR, Meyer-Monard S, Esser R, Tonn T, Soerensen J, et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant (2013) 48 (3):433-8.